SMS Pharmaceuticals Ltd

SMS Pharma. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

SMS Pharmaceuticals Ltd

₹ 252 0.82%
10 Jun - close price
smspharma.com BSE: 532815 NSE: SMSPHARMA
About

SMS Pharmaceuticals Ltd is a diversified and integrated pharmaceutical company with interests in Active Pharmaceutical Ingredients (API) and Intermediates.[1]

Key Points

Product Portfolio
It is an integrated pharmaceutical company specializing in Active Pharmaceutical Ingredients (API) and complex Intermediates, under various therapeutic categories including Anti-ulcer, anti-fungal, anti-migraine, anti-viral, anti-diabetic, anti-retroviral, etc. with global leadership position in 10+ therapeutic products. The company offers 45+ products to 800+ customers across 75+ countries. [1] [2]

Website BSE NSE
  • Market Cap ₹ 2,235 Cr.
  • Current Price ₹ 252
  • High / Low ₹ 398 / 175
  • Stock P/E 32.7
  • Book Value ₹ 75.9
  • Dividend Yield 0.16 %
  • ROCE 12.2 %
  • ROE 11.0 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 24.8%
  • Promoter holding has increased by 1.58% over last quarter.

Cons

  • Stock is trading at 3.32 times its book value
  • Company has a low return on equity of 7.39% over last 3 years.
  • Company might be capitalizing the interest cost
  • Promoters have pledged 37.6% of their holding.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
61 64 159 149 149 135 167 161 246 164 197 173 248
65 65 146 131 126 109 139 133 212 131 165 140 207
Operating Profit -4 -0 14 18 23 27 28 29 33 33 32 33 41
OPM % -7% -1% 9% 12% 16% 20% 17% 18% 14% 20% 16% 19% 17%
0 1 1 2 1 1 1 1 2 1 1 2 1
Interest 4 5 5 6 6 6 6 6 6 5 5 4 5
Depreciation 8 8 8 8 8 8 8 8 8 8 9 9 9
Profit before tax -16 -12 1 6 11 13 15 16 22 22 20 23 29
Tax % -156% -21% 12% 22% 24% 29% 21% 26% 26% 25% 28% 24% 29%
9 -10 1 5 8 9 12 12 16 16 14 17 21
EPS in Rs 1.07 -1.16 0.09 0.59 0.95 1.10 1.42 1.44 1.88 1.93 1.68 2.03 2.33
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
518 587 611 438 463 465 412 563 520 522 709 783
461 500 522 363 369 375 332 442 405 467 592 643
Operating Profit 57 86 89 75 93 90 80 121 115 55 117 140
OPM % 11% 15% 15% 17% 20% 19% 19% 22% 22% 10% 16% 18%
2 16 4 1 2 3 5 3 5 5 4 6
Interest 14 18 17 16 15 12 12 11 19 22 24 19
Depreciation 13 17 19 19 20 19 22 22 32 32 32 34
Profit before tax 32 67 56 42 60 62 51 91 69 6 66 93
Tax % 36% 48% 26% 14% 33% 34% 36% 33% 1% 26% 25% 27%
20 35 42 36 40 41 33 61 68 4 49 68
EPS in Rs 2.40 4.15 4.92 4.20 4.78 4.89 3.86 7.20 8.03 0.48 5.83 7.71
Dividend Payout % 8% 5% 4% 5% 5% 5% 6% 4% 4% 62% 7% 5%
Compounded Sales Growth
10 Years: 3%
5 Years: 14%
3 Years: 15%
TTM: 10%
Compounded Profit Growth
10 Years: 7%
5 Years: 16%
3 Years: 0%
TTM: 38%
Stock Price CAGR
10 Years: 18%
5 Years: 37%
3 Years: 45%
1 Year: 22%
Return on Equity
10 Years: 11%
5 Years: 10%
3 Years: 7%
Last Year: 11%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 8 8 8 8 8 8 8 8 8 8 8 9
Reserves 213 246 286 254 293 331 359 420 485 487 562 664
167 167 204 149 146 144 157 255 263 254 281 311
120 119 158 89 72 93 103 147 126 165 217 202
Total Liabilities 509 540 656 501 519 577 627 830 883 914 1,068 1,186
247 277 370 290 279 281 280 457 438 412 437 533
CWIP 39 29 13 8 8 18 42 7 11 33 30 35
Investments 6 13 21 37 45 45 45 45 45 45 45 45
217 221 252 166 187 232 259 321 389 424 556 573
Total Assets 509 540 656 501 519 577 627 830 883 914 1,068 1,186

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
65 59 61 73 32 50 40 90 45 22 50 82
-37 -55 -79 -39 -17 -35 -43 -152 -27 -30 -52 -123
-30 -10 27 -33 -15 -13 -2 92 -12 -32 31 47
Net Cash Flow -2 -6 9 1 0 2 -5 31 6 -39 29 5

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 39 37 36 18 19 20 43 68 34 104 122 95
Inventory Days 90 81 106 114 135 170 191 148 333 243 201 238
Days Payable 59 58 79 82 49 59 66 70 97 117 130 95
Cash Conversion Cycle 70 61 63 50 105 131 169 146 270 230 192 238
Working Capital Days 65 62 63 48 73 95 111 115 172 196 167 168
ROCE % 12% 21% 16% 13% 18% 16% 13% 17% 12% 4% 11% 12%

Shareholding Pattern

Numbers in percentages

4 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
64.17% 64.17% 64.17% 64.29% 64.32% 64.32% 64.32% 64.67% 64.67% 64.67% 64.67% 66.27%
0.63% 0.59% 0.59% 0.59% 0.67% 0.60% 0.59% 0.17% 0.18% 0.52% 0.31% 0.08%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.98% 2.13% 2.55% 2.55% 2.43%
35.20% 35.23% 35.23% 35.12% 35.01% 35.07% 35.10% 33.18% 33.03% 32.27% 32.47% 31.23%
No. of Shareholders 26,63826,49126,52625,53724,65325,24625,34130,14031,78033,13634,97335,332

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls